MBOT News & Events

Microbot Medical announced that it has achieved a significant regulatory milestone as Israel becomes the second jurisdiction - and the first outside of the U.S. - to grant marketing clearance for the Liberty System. The regulatory approval from the Israeli Ministry of Health's AMAR Division, the authority responsible for medical device regulation in Israel, allows the Company to market and commercialize the Liberty System in Israel, which also enables the Company to obtain a Free Sale Certificate to support submissions and commercial activities in additional jurisdictions. The Company continues to pursue CE Mark certification and is working toward completion by the end of 2026, in preparation for the next phase of commercial expansion into the EU market.

Microbot Medical announced that it has successfully executed its limited market release and will commence the full market release of its LIBERTY endovascular robotic system in the U.S. as planned. To date, LIBERTY has been adopted by multiple healthcare systems with dozens of hospitals in their networks. The company stated it is showcasing the system at the Society of Interventional Radiology Annual Scientific Meeting to further educate physicians and accelerate market adoption. "We successfully achieved our goals for the limited market release of the LIBERTY System, including its adoption by leading hospitals across multiple peripheral procedures, giving us the momentum to commence, as planned, the full market release at the SIR conference," said Harel Gadot, chairman and CEO. "It's exciting to see the level of enthusiasm among our existing customers, first when they initially use LIBERTY, utilizing it across multiple procedures, and then as they expand it to other hospital sites within their network."